Neha J. Pagidipati

TL;DR: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo.

TL;DR: How mortality statistics are currently collected in both developed and developing countries, the various limitations of data, and how best to assess CVD-associated mortality in settings where most people die at home without death certificates or prior health records are reviewed are elucidated.

TL;DR: Overall cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials is shown and drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns.

TL;DR: The SPYRAL HTN-OFF MED (SPYRAL Pivotal) trial showed the superiority of catheter-based renal denervation compared with a sham procedure to safely lower blood pressure in the absence of antihypertensive medications.

TL;DR: Although univariate predictors of test positivity were similar, in multivariable models, age, body mass index, and Framingham risk score were predictive of a positive test in women, whereas Framingham and Diamond and Forrester risk scores were predictive in men.